GE HealthCare Technologies Inc. (NASDAQ:GEHC) Position Lessened by Intrepid Financial Planning Group LLC

Intrepid Financial Planning Group LLC decreased its position in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 4.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 12,018 shares of the company’s stock after selling 613 shares during the period. Intrepid Financial Planning Group LLC’s holdings in GE HealthCare Technologies were worth $1,128,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in shares of GE HealthCare Technologies by 9.2% during the 1st quarter. Vanguard Group Inc. now owns 48,519,340 shares of the company’s stock valued at $4,410,893,000 after buying an additional 4,107,746 shares during the last quarter. Bank of Montreal Can lifted its stake in GE HealthCare Technologies by 27.5% in the second quarter. Bank of Montreal Can now owns 696,446 shares of the company’s stock valued at $54,964,000 after acquiring an additional 150,137 shares during the last quarter. Sei Investments Co. grew its position in GE HealthCare Technologies by 30.6% in the first quarter. Sei Investments Co. now owns 279,336 shares of the company’s stock worth $25,393,000 after acquiring an additional 65,476 shares in the last quarter. Douglas Lane & Associates LLC increased its stake in shares of GE HealthCare Technologies by 2.2% during the 3rd quarter. Douglas Lane & Associates LLC now owns 460,004 shares of the company’s stock worth $43,171,000 after purchasing an additional 10,099 shares during the last quarter. Finally, Canada Pension Plan Investment Board lifted its stake in shares of GE HealthCare Technologies by 5,075,130.0% in the 1st quarter. Canada Pension Plan Investment Board now owns 507,523 shares of the company’s stock valued at $46,139,000 after purchasing an additional 507,513 shares during the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Insider Buying and Selling

In other news, CEO Roland Rott sold 3,577 shares of the stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $86.48, for a total value of $309,338.96. Following the completion of the transaction, the chief executive officer now owns 24,298 shares in the company, valued at approximately $2,101,291.04. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.27% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have commented on GEHC shares. JPMorgan Chase & Co. started coverage on shares of GE HealthCare Technologies in a research report on Monday, September 9th. They set a “neutral” rating and a $90.00 target price on the stock. Stifel Nicolaus raised their price objective on GE HealthCare Technologies from $100.00 to $102.00 and gave the company a “buy” rating in a research note on Monday, September 30th. Evercore ISI boosted their target price on GE HealthCare Technologies from $98.00 to $102.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. UBS Group downgraded GE HealthCare Technologies from a “neutral” rating to a “sell” rating and lowered their price target for the company from $84.00 to $74.00 in a report on Thursday, September 26th. Finally, Wells Fargo & Company boosted their price objective on shares of GE HealthCare Technologies from $95.00 to $96.00 and gave the stock an “overweight” rating in a research note on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $94.36.

GE HealthCare Technologies Stock Performance

NASDAQ GEHC opened at $85.39 on Tuesday. The company’s fifty day moving average is $88.92 and its two-hundred day moving average is $83.48. GE HealthCare Technologies Inc. has a 52-week low of $66.39 and a 52-week high of $94.55. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.23 and a quick ratio of 0.98. The firm has a market capitalization of $39.01 billion, a price-to-earnings ratio of 23.46, a P/E/G ratio of 3.08 and a beta of 1.24.

GE HealthCare Technologies (NASDAQ:GEHC) last released its earnings results on Wednesday, October 30th. The company reported $1.14 earnings per share for the quarter, topping analysts’ consensus estimates of $1.06 by $0.08. The business had revenue of $4.86 billion for the quarter, compared to the consensus estimate of $4.87 billion. GE HealthCare Technologies had a return on equity of 25.19% and a net margin of 8.56%. The firm’s revenue for the quarter was up .9% compared to the same quarter last year. During the same period last year, the business earned $0.99 earnings per share. Equities research analysts forecast that GE HealthCare Technologies Inc. will post 4.29 EPS for the current year.

GE HealthCare Technologies Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, November 15th. Investors of record on Friday, October 18th will be paid a $0.03 dividend. The ex-dividend date of this dividend is Friday, October 18th. This represents a $0.12 dividend on an annualized basis and a dividend yield of 0.14%. GE HealthCare Technologies’s payout ratio is 3.30%.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.